FDA BIOEQUIVALENCE REQUIREMENTS FOR GENERIC DIAZEPAM SHOULD INCLUDE SITE-OF-ACTION PHARMACODYNAMIC STUDIES, ROCHE TELLS FDA; VALIUM OFF PATENT

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".